|Webcasts|August 5, 2020

Virtualizing Clinical Trials in a Pandemic: Lessons Learned and What It Means to the Future of R&D

In this webcast we will explore how the required adoption of virtual recruiting, telemedicine, remote monitoring and at-home healthcare visits have taught us valuable lessons about how to run more agile and adaptive trials; and how these learnings will shape the future of R&D. Live: Thursday, Sept. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 24, 2021.

Register free: http://www.appliedclinicaltrialsonline.com/act_w/virtualizing

Event Overview:
The impact of COVID-19 on clinical trials has been substantial. For example, travel bans and site closures have forced a rapid shift in the running of physical clinical investigative sites toward purely virtual environments. While the concept of virtual clinical trials has been around for a number of years, the decision to actually run a trial has remained somewhat optional. Now, sponsors are now finding themselves forced into either fully virtualized trials and/or hybrid trials, out of necessity. However, there are silver linings – especially when it comes to the potential for adapting quickly to unforeseen situations like remaining efficient and profitable amidst a pandemic.

Key Learning Objectives:

How COVID-19 has impacted trial operations across the globe

How trial sites have adapted through the use of virtual trial elements
The challenges both sponsors and CROs have faced in this process – and how to overcome them
Which technologies/solutions generate the most benefits, and which ones do not
How lessons learned during COVID-19 can be incorporated into clinical operations plans and protocols to ensure adaptiveness and R&D efficiencies in the face of future crises

Speakers: Graham Belgrave, Senior Vice President, Head of European Operations, Advanced Clinical

Domantas Gurevicius, Senior Director, Clinical Monitoring, Advanced Clinical

Time and date: Thursday, Sept. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

On demand available after airing until Sept. 24, 2021.

Sponsor: Advanced Clinical

Register free: http://www.appliedclinicaltrialsonline.com/act_w/virtualizing

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 30th, 2026

The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials

AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.

© FlowStudio - © FlowStudio - stock.adobe.com

September 29th, 2026

Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.

September 29th, 2026

The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.

September 29th, 2026

ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

September 28th, 2026

Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD

In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.

September 28th, 2026

The Design Flaws Trial Simulations Surface That Traditional Planning Misses

In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.